Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Avacopan in Normal Renal Function and ESRD Requiring Hemodialysis
NCT06468826Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avacopan in end stage renal disease (ESRD) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration of Avacopan at Day 18, Maximum Observed Plasma Concentration of Metabolite M1 at Day 18 and 8 more. Started Jun 2024; status: completed.
02
Drugs
avacopan
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT06468826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06468826.